Travere Therapeutics CCO sells 2,662 shares at $30 under 10b5-1

Travere Therapeutics (TVTX) reported an insider transaction by its Chief Commercial Officer.

Accepted by SEC EDGAR 10/30/2025 - 04:45 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Travere Therapeutics (TVTX) reported an insider transaction by its Chief Commercial Officer. On 10/28/2025, the officer sold 2,662 shares of common stock at $30 per share (transaction code S), leaving 124,662 shares beneficially owned directly after the sale.

The filing notes the sale was made under a Rule 10b5-1(c) trading plan adopted on June 16, 2025.

Insider Trade Summary

Net Seller: 2,662 shares

Net Sell 1 txn

Insider Heerma Peter

Role CHIEF COMMERCIAL OFFICER

Sold 2,662 shs ($80K)

Share of Position Sold 2.1%

Type	Security	Shares	Price	Value
Sale	Common Stock	2,662	$30.00	$80K

Holdings After Transaction: Common Stock — 124,662 shares (Direct)

Holdings Before and After: Common Stock, 127,324 to 124,662 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TVTX report?

The Chief Commercial Officer sold 2,662 shares of common stock at $30 on 10/28/2025.

How many Travere Therapeutics (TVTX) shares does the insider hold after the sale?

Following the transaction, the officer beneficially owns 124,662 shares directly.

Was the TVTX insider sale under a Rule 10b5-1 plan?

Yes. The sale was made pursuant to a Rule 10b5-1(c) plan adopted on June 16, 2025.

What was the transaction code and price for the TVTX Form 4 sale?

Transaction code S (sale) at a price of $30 per share.

What is the insider’s role at Travere Therapeutics (TVTX)?

The reporting person is the Chief Commercial Officer.

What is the ownership form reported for the remaining TVTX shares?

The ownership form is Direct (D).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heerma Peter

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, SUITE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF COMMERCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/28/2025		S(1)		2,662	D	$30	124,662	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	10/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.